RecruitingNCT06541652

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Sponsor

Federation Francophone de Cancerologie Digestive

Enrollment

150 participants

Start Date

Mar 26, 2024

Study Type

OBSERVATIONAL

Conditions

Cholangiocarcinoma Hepatoblastoma Fibrolamellar Carcinoma Hepatocholangiocarcinoma Hepatic Epithelioid Hemangioendothelioma Hepatic Neuroendocrine Carcinoma Hepatic Carcinosarcomas Hepatic Cystadenoma Hepatic Leiomyosarcomas Hepatic Angiosarcomas

Summary

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is collecting data on patients in France who have been diagnosed with rare types of primary liver cancer — including hepato-cholangiocarcinoma (a mixed liver-bile duct cancer), fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, and hepatic angiosarcoma. These cancers are so uncommon that data on treatments and outcomes is very limited, and this registry aims to fill that gap. **You may be eligible if...** - You are 18 or older - You have been diagnosed with one of the four specific rare liver cancer types, confirmed by biopsy - Your diagnosis was made after January 1, 2018 - You are living (or recently deceased) and covered by French social security **You may NOT be eligible if...** - You do not have one of the four specified rare liver cancer types - Your cancer was diagnosed before January 2018 - A tumor tissue block is not available for research use - You are not covered by French social security Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(40)

CHU Amiens picardie

Amiens, France

Chu Angers

Angers, France

Ch - Centresimone Veil de Beauvais

Beauvais, France

Chu Jean Minjoz

Besançon, France

Ch Bethune Beuvry

Béthune, France

Avicenne

Bobigny, France

Cote de Nacre

Caen, France

Centre Hospitalier

Calais, France

Chu de Clichy Hopital Beaujon

Clichy, France

Centre Hospitalier Universitaire Henri Mondor

Créteil, France

CHU

Dijon, France

Chu Grenobles Alpes

La Tronche, France

Centre Hospital Universitaire de lille

Lille, France

Longjumeau Ch Nord Essone

Longjumeau, France

Ch Edouard Herriot

Lyon, France

Centre Léon Berard

Lyon, France

La Clinique de La Sauvegarde

Lyon, France

Chu Edouard Herriot

Lyon, France

Lyon Cac Leon Berard

Lyon, France

Lyon La Croix Rousse

Lyon, France

Hopital Saint Joseph

Marseille, France

Chu de La Timone

Marseille, France

CHR - Metz Thionville Hopital de Mercy

Metz, France

CHU La Source

Orléans, France

Chu de Paris Saint Antoine

Paris, France

AP - HP - Pitié Salpêtrière

Paris, France

PAU CH

Pau, France

Centre Hospitalier de Perpignan

Perpignan, France

Hopital Haut Leveque

Pessac, France

Chu de Poitiers

Poitiers, France

CH - Annecy Genevois

Pringy, France

Chu Robert Debre

Reims, France

CAC - Eugène Marquis

Rennes, France

Ico Site Rene Gauducheau

Saint-Herblain, France

Hopital Nord Chu Saint Etienne

Saint-Priest-en-Jarez, France

Groupe Hospitalier Rance Emeraude

St-Malo, France

Chu Rangueil

Toulouse, France

Chru de Tours

Tours, France

Chu Paul Brousse

Villejuif, France

Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06541652

Related Trials

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT046451601 location

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

NCT072063551 location

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

NCT070301401 location

FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

NCT074785231 location

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location